TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Trial Comparing the Efficacy and Safety of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily With Tiotropium 18 mcg Once Daily Over 24 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The purpose of this 24 week study is to evaluate the spirometric lung function effect (trough FEV1) of Umeclidinium/Vilanterol 62.5/25 once daily compared to Tiotropium 18 mcg once daily along with safety assessments in subjects with COPD.


Options:
A: Arm Label: UMEC (62.5 mcg); Type: EXPERIMENTAL; Interventions: Drug: UMEC DPI, Drug: ICS/LABA medication, Drug: Albuterol/salbutamol Metered Dose Inhaler (MDI) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo DPI, Drug: ICS/LABA medication, Drug: Albuterol/salbutamol Metered Dose Inhaler (MDI) | Intervention Type: DRUG; Name: UMEC DPI; Assigned to Arm(s): UMEC (62.5 mcg) | Intervention Type: DRUG; Name: Placebo DPI; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: ICS/LABA medication; Assigned to Arm(s): Placebo, UMEC (62.5 mcg) | Intervention Type: DRUG; Name: Albuterol/salbutamol Metered Dose Inhaler (MDI); Assigned to Arm(s): Placebo, UMEC (62.5 mcg)
B: Arm Label: Umeclidinium/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium/Vilanterol 62.5/25 mcg | Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 mcg | Intervention Type: DRUG; Name: Umeclidinium/Vilanterol 62.5/25 mcg; Assigned to Arm(s): Umeclidinium/Vilanterol | Intervention Type: DRUG; Name: Tiotropium 18 mcg; Assigned to Arm(s): Tiotropium
C: Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719
D: Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: 3% Hypertonic Saline to Reduce Hospitalization Rate in Acute Viral Bronchiolitis: a Randomized Double Blind Clinical Trial
Brief Summary: The purpose of this study is to determine whether nebulized hypertonic saline solution reduces the admission rate 48 hours after initial treatment in the emergency department, when compared to normal saline solution (control).


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: solution contains 1 mg salbutamol plus 3% hypertonic saline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: solution contains 1 mg salbutamol plus 0.9% saline | Intervention Type: DRUG; Name: solution contains 1 mg salbutamol plus 3% hypertonic saline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: solution contains 1 mg salbutamol plus 0.9% saline; Assigned to Arm(s): 2
B: Arm Label: 3% Saline; Type: EXPERIMENTAL; Interventions: Drug: 3% Saline | Arm Label: 0.9% Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Normal Saline | Intervention Type: DRUG; Name: 3% Saline; Assigned to Arm(s): 3% Saline | Intervention Type: DRUG; Name: 0.9% Normal Saline; Assigned to Arm(s): 0.9% Normal Saline
C: Arm Label: NaCl 3% inhalations + standard therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: NaCl 3%, Other: Standard therapy | Arm Label: Standard therapy; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard therapy | Intervention Type: DRUG; Name: NaCl 3%; Assigned to Arm(s): NaCl 3% inhalations + standard therapy | Intervention Type: OTHER; Name: Standard therapy; Assigned to Arm(s): NaCl 3% inhalations + standard therapy, Standard therapy
D: Arm Label: Standard Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: L-Epinephrine and Normal Saline (0.9%) | Arm Label: Study Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: L-Epinephrine and Hypertonic Saline (3%) | Intervention Type: DRUG; Name: L-Epinephrine and Normal Saline (0.9%); Assigned to Arm(s): Standard Treatment | Intervention Type: DRUG; Name: L-Epinephrine and Hypertonic Saline (3%); Assigned to Arm(s): Study Treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: 3% Hypertonic Saline to Reduce Hospitalization Rate in Acute Viral Bronchiolitis: a Randomized Double Blind Clinical Trial
Brief Summary: The purpose of this study is to determine whether nebulized hypertonic saline solution reduces the admission rate 48 hours after initial treatment in the emergency department, when compared to normal saline solution (control).


Options:
A: Arm Label: Nebulized Hypertonic Saline; Type: EXPERIMENTAL; Interventions: Drug: 3% sodium chloride | Arm Label: Nebulized Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% sodium chloride | Intervention Type: DRUG; Name: 3% sodium chloride; Assigned to Arm(s): Nebulized Hypertonic Saline | Intervention Type: DRUG; Name: 0.9% sodium chloride; Assigned to Arm(s): Nebulized Normal Saline
B: Arm Label: 3% Saline; Type: EXPERIMENTAL; Interventions: Drug: 3% Saline | Arm Label: 0.9% Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Normal Saline | Intervention Type: DRUG; Name: 3% Saline; Assigned to Arm(s): 3% Saline | Intervention Type: DRUG; Name: 0.9% Normal Saline; Assigned to Arm(s): 0.9% Normal Saline
C: Arm Label: Normal saline and epinephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Normal saline and epinephrine | Arm Label: Hypertonic saline and epinephrine; Type: EXPERIMENTAL; Interventions: Drug: Hypertonic saline and epinephrine | Intervention Type: DRUG; Name: Hypertonic saline and epinephrine; Assigned to Arm(s): Hypertonic saline and epinephrine | Intervention Type: DRUG; Name: Normal saline and epinephrine; Assigned to Arm(s): Normal saline and epinephrine
D: Arm Label: hypertonic saline and usual care; Type: ACTIVE_COMPARATOR; Interventions: Device: 3% hypertonic saline | Arm Label: usual care (oxygen therapy); Type: ACTIVE_COMPARATOR; Interventions: Device: 3% hypertonic saline | Intervention Type: DEVICE; Name: 3% hypertonic saline; Assigned to Arm(s): hypertonic saline and usual care, usual care (oxygen therapy)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIa, Open Label, Dose-escalating Clinical Study to Evaluate the Safety, Tolerability and Therapeutic Effects of Transplantation of Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS).
Brief Summary: The study will evaluate the safety, tolerability and therapeutic effects of transplantation of escalating doses of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF), in patients with amyotrophic lateral sclerosis (ALS).


Options:
A: Arm Label: Transplant; Type: EXPERIMENTAL; Interventions: Procedure: Laminectomy and bone marrow stem cells transplantation, Procedure: Autologous bone marrow cells collection | Intervention Type: PROCEDURE; Name: Laminectomy and bone marrow stem cells transplantation; Assigned to Arm(s): Transplant | Intervention Type: PROCEDURE; Name: Autologous bone marrow cells collection; Assigned to Arm(s): Transplant
B: Arm Label: MSC-NTF; Type: EXPERIMENTAL; Interventions: Biological: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF | Intervention Type: BIOLOGICAL; Name: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF; Assigned to Arm(s): MSC-NTF
C: Arm Label: MSC-NTF cells IM; Type: EXPERIMENTAL; Interventions: Biological: MSC-NTF cells transplantation (IM) | Arm Label: MSC-NTF cells IT; Type: EXPERIMENTAL; Interventions: Biological: MSC-NTF cells transplantation (IT) | Intervention Type: BIOLOGICAL; Name: MSC-NTF cells transplantation (IM); Assigned to Arm(s): MSC-NTF cells IM | Intervention Type: BIOLOGICAL; Name: MSC-NTF cells transplantation (IT); Assigned to Arm(s): MSC-NTF cells IT
D: Arm Label: Treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously; Type: EXPERIMENTAL; Interventions: Biological: Injection of autologous bone marrow derived mesenchymal stem cells | Intervention Type: BIOLOGICAL; Name: Injection of autologous bone marrow derived mesenchymal stem cells; Assigned to Arm(s): Treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIa, Open Label, Dose-escalating Clinical Study to Evaluate the Safety, Tolerability and Therapeutic Effects of Transplantation of Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS).
Brief Summary: The study will evaluate the safety, tolerability and therapeutic effects of transplantation of escalating doses of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF), in patients with amyotrophic lateral sclerosis (ALS).


Options:
A: Arm Label: MSC-NTF; Type: EXPERIMENTAL; Interventions: Biological: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF | Intervention Type: BIOLOGICAL; Name: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF; Assigned to Arm(s): MSC-NTF
B: Arm Label: MSC-NTF cells IM; Type: EXPERIMENTAL; Interventions: Biological: MSC-NTF cells transplantation (IM) | Arm Label: MSC-NTF cells IT; Type: EXPERIMENTAL; Interventions: Biological: MSC-NTF cells transplantation (IT) | Intervention Type: BIOLOGICAL; Name: MSC-NTF cells transplantation (IM); Assigned to Arm(s): MSC-NTF cells IM | Intervention Type: BIOLOGICAL; Name: MSC-NTF cells transplantation (IT); Assigned to Arm(s): MSC-NTF cells IT
C: Arm Label: stem cell reciepient; Type: EXPERIMENTAL; Interventions: Biological: intra venous injection of stem cell | Intervention Type: BIOLOGICAL; Name: intra venous injection of stem cell; Assigned to Arm(s): stem cell reciepient
D: Arm Label: Transplant; Type: EXPERIMENTAL; Interventions: Procedure: Laminectomy and bone marrow stem cells transplantation, Procedure: Autologous bone marrow cells collection | Intervention Type: PROCEDURE; Name: Laminectomy and bone marrow stem cells transplantation; Assigned to Arm(s): Transplant | Intervention Type: PROCEDURE; Name: Autologous bone marrow cells collection; Assigned to Arm(s): Transplant

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of NAC Supplementation on Skeletal Muscle Performance Following Aseptic Injury Induced by Exercise
Brief Summary: In this investigation the investigators utilized NAC administration to foster GSH availability during an 8-day period following eccentric exercise-induced muscle damage in order to test our hypotheses: i) antioxidant supplementation does not disturb performance and adaptations induced by exercise-induced muscle injury and ii) redox status perturbations in skeletal muscle are pivotal for the regulation of muscle' inflammatory response and repair.


Options:
A: Arm Label: n-acetylcysteine/placebo supplementation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: n-acetylcysteine supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: n-acetylcysteine supplementation; Assigned to Arm(s): n-acetylcysteine/placebo supplementation
B: Arm Label: vitamins minerals; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Taking of blood, Dietary Supplement: needle biopsy of the vastus lateralis muscle, Dietary Supplement: Vit C Vit E Zn Se | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Taking of blood, Dietary Supplement: needle biopsy of the vastus lateralis muscle, Dietary Supplement: Placebo Vit E Placebo Vit C Zn Se | Intervention Type: PROCEDURE; Name: Taking of blood; Assigned to Arm(s): Placebo, vitamins minerals | Intervention Type: DIETARY_SUPPLEMENT; Name: needle biopsy of the vastus lateralis muscle; Assigned to Arm(s): Placebo, vitamins minerals | Intervention Type: DIETARY_SUPPLEMENT; Name: Vit C Vit E Zn Se; Assigned to Arm(s): vitamins minerals | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo Vit E Placebo Vit C Zn Se; Assigned to Arm(s): Placebo
C: Arm Label: 9 elite weightlifters; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Natural Pomegranate Juice | Arm Label: 9elite weightlifters; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo Juice | Intervention Type: DIETARY_SUPPLEMENT; Name: Natural Pomegranate Juice; Assigned to Arm(s): 9 elite weightlifters | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo Juice; Assigned to Arm(s): 9elite weightlifters
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin C, Vitamin E | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Antioxidant treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin C, Vitamin E; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Antioxidant treatment; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times (ESCAPE) Trial
Brief Summary: The purpose of the study is to understand whether a new treatment of stroke - endovascular clot removal - can be added to the current standard of care to improve patient outcomes.

All patients will receive the best standard stroke treatment. This includes treating patients with the clot dissolving drug tPA (tissue plasminogen activator). However, t-PA does not work in some patients and others are not eligible to receive t-PA because they present too late for treatment (they woke up with their stroke symptoms or their stroke was not witnessed).

During endovascular revascularization the blockage in the artery is removed with the use of devices called stentreivers and or by giving clot dissolving drug at the site of the blockage in the artery to restore blood flow. Stentrievers are devices that have been designed by different companies to remove blood clots from arteries.

Up to a maximum of 500 people at 20-25 hospitals across Canada and other countries will participate in this study.


Options:
A: Arm Label: Penumbra System with Separator 3D; Type: EXPERIMENTAL; Interventions: Device: Penumbra System with Separator 3D | Arm Label: Penumbra System alone; Type: ACTIVE_COMPARATOR; Interventions: Device: Penumbra System alone | Intervention Type: DEVICE; Name: Penumbra System with Separator 3D; Assigned to Arm(s): Penumbra System with Separator 3D | Intervention Type: DEVICE; Name: Penumbra System alone; Assigned to Arm(s): Penumbra System alone
B: Arm Label: Intra-arterial Clot Retrieval after iv tPA; Type: EXPERIMENTAL; Interventions: Device: Intra-arterial Clot Retrieval with Solitaire device | Arm Label: Standard care iv tPA; Type: ACTIVE_COMPARATOR; Interventions: Genetic: intravenous tissue plasminogen activator (tPA) | Intervention Type: DEVICE; Name: Intra-arterial Clot Retrieval with Solitaire device; Assigned to Arm(s): Intra-arterial Clot Retrieval after iv tPA | Intervention Type: GENETIC; Name: intravenous tissue plasminogen activator (tPA); Assigned to Arm(s): Standard care iv tPA
C: Arm Label: Direct MT; Type: SHAM_COMPARATOR; Interventions: Procedure: intra-arterial thrombectomy | Arm Label: IVT combine with MT; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intra-arterial thrombectomy, Drug: Intravenous thrombolysis | Intervention Type: PROCEDURE; Name: intra-arterial thrombectomy; Assigned to Arm(s): Direct MT, IVT combine with MT | Intervention Type: DRUG; Name: Intravenous thrombolysis; Assigned to Arm(s): IVT combine with MT
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Endovascular thrombectomy/thrombolysis; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular thrombectomy/thrombolysis | Intervention Type: PROCEDURE; Name: Endovascular thrombectomy/thrombolysis; Assigned to Arm(s): Endovascular thrombectomy/thrombolysis

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times (ESCAPE) Trial
Brief Summary: The purpose of the study is to understand whether a new treatment of stroke - endovascular clot removal - can be added to the current standard of care to improve patient outcomes.

All patients will receive the best standard stroke treatment. This includes treating patients with the clot dissolving drug tPA (tissue plasminogen activator). However, t-PA does not work in some patients and others are not eligible to receive t-PA because they present too late for treatment (they woke up with their stroke symptoms or their stroke was not witnessed).

During endovascular revascularization the blockage in the artery is removed with the use of devices called stentreivers and or by giving clot dissolving drug at the site of the blockage in the artery to restore blood flow. Stentrievers are devices that have been designed by different companies to remove blood clots from arteries.

Up to a maximum of 500 people at 20-25 hospitals across Canada and other countries will participate in this study.


Options:
A: Arm Label: Best standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Best standard treatment | Arm Label: Mechanical thrombectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: mechanical thrombectomy | Intervention Type: PROCEDURE; Name: mechanical thrombectomy; Assigned to Arm(s): Mechanical thrombectomy | Intervention Type: DRUG; Name: Best standard treatment; Assigned to Arm(s): Best standard treatment
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: local interarterial recombinant tissue plasminogen activator | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous (IV) rt-PA | Intervention Type: DRUG; Name: local interarterial recombinant tissue plasminogen activator; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: intravenous (IV) rt-PA; Assigned to Arm(s): 2
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Endovascular thrombectomy/thrombolysis; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular thrombectomy/thrombolysis | Intervention Type: PROCEDURE; Name: Endovascular thrombectomy/thrombolysis; Assigned to Arm(s): Endovascular thrombectomy/thrombolysis
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: IV tpa (Alteplase) vs IA tpa (Alteplase) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV tpa (Alteplase) vs IA tpa (Alteplase) | Intervention Type: DRUG; Name: IV tpa (Alteplase) vs IA tpa (Alteplase); Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times (ESCAPE) Trial
Brief Summary: The purpose of the study is to understand whether a new treatment of stroke - endovascular clot removal - can be added to the current standard of care to improve patient outcomes.

All patients will receive the best standard stroke treatment. This includes treating patients with the clot dissolving drug tPA (tissue plasminogen activator). However, t-PA does not work in some patients and others are not eligible to receive t-PA because they present too late for treatment (they woke up with their stroke symptoms or their stroke was not witnessed).

During endovascular revascularization the blockage in the artery is removed with the use of devices called stentreivers and or by giving clot dissolving drug at the site of the blockage in the artery to restore blood flow. Stentrievers are devices that have been designed by different companies to remove blood clots from arteries.

Up to a maximum of 500 people at 20-25 hospitals across Canada and other countries will participate in this study.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Endovascular thrombectomy/thrombolysis; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular thrombectomy/thrombolysis | Intervention Type: PROCEDURE; Name: Endovascular thrombectomy/thrombolysis; Assigned to Arm(s): Endovascular thrombectomy/thrombolysis
B: Arm Label: general anesthesia; Type: EXPERIMENTAL; Interventions: Drug: Etomidate, Drug: Succinylcholine, Drug: Propofol, Drug: Remifentanil | Arm Label: sedation; Type: EXPERIMENTAL; Interventions: Drug: Remifentanil, Drug: Lidocaine | Intervention Type: DRUG; Name: Etomidate; Assigned to Arm(s): general anesthesia | Intervention Type: DRUG; Name: Succinylcholine; Assigned to Arm(s): general anesthesia | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): general anesthesia | Intervention Type: DRUG; Name: Remifentanil; Assigned to Arm(s): general anesthesia, sedation | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): sedation
C: Intervention Type: DRUG; Name: rt-PA 0.9 mg/kg verum or placebo Intravenous; Assigned to Arm(s): N/A
D: Arm Label: intravenous (IV) rt-PA alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV rt-PA alone | Arm Label: Endovascular therapy; Type: EXPERIMENTAL; Interventions: Drug: IV rt-PA alone, Other: endovascular therapy | Intervention Type: DRUG; Name: IV rt-PA alone; Assigned to Arm(s): Endovascular therapy, intravenous (IV) rt-PA alone | Intervention Type: OTHER; Name: endovascular therapy; Assigned to Arm(s): Endovascular therapy

Answer: A